Article Figures & Data
Figures
- FIGURE 1.
Histograms of distribution of SUVmax of tumor site on early images (A), SUVmax on delayed images (B), and percentage SUVmax change between early and delayed scans (C). Line represents gaussian fit to distribution.
- FIGURE 2.
Relationship between various cutoff of percentage changes of SUVmax and their discriminative value for overall survival, as assessed by log-rank test.
- FIGURE 3.
Transaxial PET images of 2 patients at early (left) and delayed (right) scans. Histopathology, in both cases, was moderately differentiated adenocarcinoma. Percentage change of SUVmax, between early and delayed scans, measures 4.3% for patient in A and 36.4% for patient in B. Survival for patient in A was 28 mo, and for patient in B it was 12 mo.
- FIGURE 4.
Kaplan–Meier survival plots of patients with adenocarcinoma of lung by clinical stage (stages I–II, compared with stages III–IV, P = 0.001) (A), presence of metastasis (P = 0.0005) (B), and percentage change of SUVmax (dichotomized using value of 25%, P = 0.0002) (C).
Tables
Factor n Percentage Median Range Age (y) 71 32–92 Sex Male 58 58% Female 42 42% Albumin (g/dL) 3.5 1.6–9 Calcium (mmol/L) 2.4 1.8–3.4 Hemoglobin (g/dL) 11.9 6.6–16.4 Platelets (×10 9/L) 228.5 32–854 White blood cells (×10 9/L) 14.1 3.8–32.4 Grading Well differentiated 12 12% Differentiated 27 27% Poorly differentiated 20 20% Undifferentiated 15 15% Unknown 26 26% Stage (n = 64) IA 13 IB 8 IIA 6 IIB 4 IIIA 14 IIIB 9 IV 10 SUVmax1 5.5 1.7–27.1 SUVmax2 7.2 1.8–29.9 SUV change 18.8% −28.6%−66.7% All patients (n = 100) had histologically proven adenocarcinoma of the lung.
- TABLE 2
Univariate Kaplan–Meier Analysis of Overall Survival in Patients with Lung Adenocarcinoma
Factor n Median survival (mo) 95% Confidence interval for mean (mo) Hazard ratio (%) Cumulative survival proportions at 60 mo P (log-rank) Age (y) 0.36 0.01 <60 21 71 45–70 42 ≥60 79 26 24–33 7 Sex 0.84 0.05 Male 58 31 28–44 28 Female 42 22 23–38 21 Albumin (g/dL) 0.70 0.05 <3.5 26 26 17–38 14 ≥3.5L 25 36 30–45 21 Calcium (mmol/L) 0.20 0.01 <2.5 45 38 33–46 15 ≥2.5 13 18 11–21 1 Hemoglobin (g/dL) 0.71 0.05 <9 20 23 18–31 10 ≥9 45 35 27–49 22 Platelets 1.80 0.007 <160 × 10 9/L 14 18 11–31 11 ≥160 × 10 9/L 51 31 30–41 38 White blood cells 0.92 0.04 <12.5 × 10 9/L 24 32 26–42 21 ≥12.5 × 10 9/L 40 21 16–32 9 Differentiation 0.63 0.04 Well; moderate 39 28 19–35 12 Poor 20 9 6–24 5 Staging 0.46 0.001 I–II 33 39 33–45 18 III–IV 31 24 18–31 Zero Size (cm) 2.01 0.01 <3 56 41 35–54 35 ≥3 44 19 16–32 9 Lymph node 0.40 0.02 No 30 41 31–54 33 Yes 34 19 17–28 6 Metastasis 0.42 0.0005 No 54 37 34–48 41 Yes 10 15 11–27 6 SUVmax1 0.62 0.04 <10 78 31 28–48 26 ≥10 22 20 13–27 17 SUVmax2 0.68 0.05 <10 83 33 31–45 21 ≥10 17 19 11–21 17 SUVmax change 0.40 0.0002 <25% 64 39 35–50 27 ≥25% 36 15 12–28 6 - TABLE 3
Multivariate Cox Regression Analysis of Overall Survival in Patients with Lung Adenocarcinoma
Factor Relative risk* 95% Confidence interval SE P Platelets 1.15 1.42–2.04 0.39 0.05 Staging 2.15 1.63–2.83 0.58 0.04 Metastasis 1.32 1.04–1.53 0.43 0.02 Percentage SUVmax change 1.52 1.14–1.90 0.32 0.01 ↵* Relative risk values are calculated at 60 mo.
Jump to section
Related Articles
Cited By...
- Prediction of Survival by [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial
- Underestimated Role of 18F-FDG PET for HCC Evaluation and Promise of 18F-FDG PET/MR Imaging in This Setting